spacer
home > ebr > spring 2002 > prevention and cure - intellectual property due diligence and warranties in biotechnology and pharmaceutical technology transfer agreements
PUBLICATIONS
European Biopharmaceutical Review

Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements

Part one of this article, which appeared in the last edition of EBR (1), was concerned with the function and importance of intellectual property due diligence in the context of biotechnology and pharmaceutical technology transfer agreements. Having looked at this crucial aspect of the pre-contract process, this second part of the series focuses on the closely related topic of contractual warranties and considers some 'frequently asked questions'.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property and Information Technology Law with Taylor Joynson Garrett

Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, and has a particular focus on clients in the pharmaceutical, biotechnology and information technology sectors. He has a Diploma in Intellectual Property Law and Practice from Bristol University, UK.

Daniel has a degree from Cambridge University in Computer Science and Physics and worked as a Computer Programmer before qualifying as a Solicitor.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement